Hepatology 2020-Jun
Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
De link wordt op het klembord opgeslagen
Sleutelwoorden
Abstract
We read with great interest the observations made by Montalvo-Gordon and colleagues regarding the potential of SGLT-2 inhibitors to ameliorate ascites and peripheral edema in patients with cirrhosis and concomitant type 2 diabetes mellitus (T2DM), serving also as an alternative treatment option in patients with diuretic-resistant or diuretic-intractable ascites. Interestingly, all 3 patients remained free of ascites and edema 12-26 months after diuretics' discontinuation, replaced by a SGLT-2 inhbitor.